ArticleScientific reports2025
Chlorogenic acid attenuates oxidative damage in rat lacrimal gland epithelial cells via PI3K/AKT/FoxO3 signaling: network pharmacology and experimental evidence.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Pharmacological effect of rhCC16 on COPD: anti-senescence via the PI3K-AKT-mTOR pathway.Molecular and cellular biochemistry · 2026Article
- Chlorogenic Acid as a Modulator of Adipose Tissue Function and Metabolic Homeostasis: Evidence from Preclinical Studies.Nutrients · 2026Review
- Wogonoside alleviates hyperosmotic stress-induced inflammation and apoptosis in human corneal epithelial cells via PI3K/AKT signaling.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Oxidative stress and inflammation are crucial in dry eye pathogenesis. The antioxidant and anti-inflammatory activities of chlorogenic acid (CGA) have been studied in various fields, including ophthalmology. However, its therapeutic effects on dry eye remain unclear. This study aims to predict and validate the mechanisms of CGA in treating dry eye through data mining and in vitro experiments. Data mining integrated multiple online databases to predict potential therapeutic targets of CGA for dry eye and performed target enrichment analysis. In vitro experiments involved dividing rat lacrimal gland epithelial cells (LGECs) into seven groups: (1) control, (2) H2O2 model (200µM), (3) H2O2 + AKT inhibitor (MK-2206, 2.5µM), (4) H2O2 + AKT activator (SC79, 10ng/ml), (5) H2O2 + CGA (500nM), (6) H2O2 + AKT inhibitor + CGA, (7) H2O2 + AKT activator + CGA. We measured cell viability, mitochondrial ROS, PI3K/AKT/FoxO3 pathway proteins, and key indicators like Caspase3, TRAIL, Bcl-2, and SOD2. Results showed that CGA treatment and AKT activation could activate the PI3K/AKT/FoxO3 pathway, reduce ROS in LGECs, increase SOD2 production, and inhibit apoptosis. These findings suggest CGA as a promising candidate for further research in dry eye prevention and treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.